Pfizer (PFE) vs Vertex Pharmaceuticals (VRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Vertex Pharmaceuticals (VRTX) has outperformed Pfizer (PFE) over the past year, gaining 20.7% versus a gain of 9.4%. Over five years, VRTX leads with a +180.5% price change compared with -49.3% for PFE. Pfizer is the larger company by market cap ($156.18 billion vs $130.58 billion), about 1.2 times the size, while Vertex Pharmaceuticals is growing revenue faster (+8.9% vs -1.6%).
On valuation, Pfizer trades at a lower forward P/E (9.3x vs 25.9x for Vertex Pharmaceuticals). Pfizer pays a dividend yielding 7.85%, while Vertex Pharmaceuticals does not currently pay one. Vertex Pharmaceuticals converts more of its revenue into profit, with a net margin of 32.9% versus 12.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PFE | VRTX |
|---|---|---|
| Share price | $27.40 | $515.02 |
| Market cap | $156.18B | $130.58B |
| 1-day change | -0.51% | -1.08% |
| YTD return | +10.04% | +13.60% |
| 1-year return | +9.42% | +20.68% |
| 5-year return | -49.26% | +180.53% |
| P/E ratio (TTM) | 39.14 | 33.14 |
| Forward P/E | 9.28 | 25.86 |
| EPS (TTM) | $0.70 | $15.54 |
| Dividend yield | 7.85% | 0.00% |
| Annual dividend | $2.15 | $0.00 |
| Revenue (latest FY) | $62.58B | $12.00B |
| Revenue growth (YoY) | -1.65% | +8.90% |
| Net income (latest FY) | $7.77B | $3.95B |
| Gross margin | 74.33% | 86.24% |
| Operating margin | — | 34.77% |
| Net margin | 12.42% | 32.94% |
| 52-week high | $31.44 | $568.67 |
| 52-week low | $23.62 | $412.27 |
| Distance from 52-week high | -12.85% | -9.43% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +10.29% | +15.60% |
| Average volume | 33.52M | 1.25M |
| Shares outstanding | 5.70B | 253.54M |
| Employees | 75,000 | 6,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VRTX has outperformed PFE by 11.3 percentage points over the past year.
- Pfizer offers a meaningfully higher dividend yield (7.85% vs 0.00%).
- Vertex Pharmaceuticals is more profitable, keeping 32.9 cents of every revenue dollar as net income versus 12.4 cents for Pfizer.
- Vertex Pharmaceuticals grew revenue faster in its latest fiscal year (+8.90% vs -1.65%).
About Pfizer
PFE stock →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees
About Vertex Pharmaceuticals
VRTX stock →Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 6,400 employees
PFE vs VRTX FAQ
Which is bigger, Pfizer or Vertex Pharmaceuticals?
Pfizer (PFE) is larger, with a market capitalization of $156.18B compared with $130.58B for Vertex Pharmaceuticals (VRTX).
Which stock has performed better over the past year, PFE or VRTX?
VRTX returned +20.68% over the past 12 months, compared with +9.42% for PFE (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, PFE or VRTX?
VRTX has the lower trailing P/E at 33.1, versus 39.1 for PFE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Pfizer or Vertex Pharmaceuticals?
Pfizer pays a dividend yielding 7.85%, while Vertex Pharmaceuticals does not currently pay a regular dividend.
Are Pfizer and Vertex Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.